Navigation Links
VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
Date:2/5/2013

NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013

http://www.reportlinker.com/p0656768/VEGF-Inhibition-Therapy-Indicating-and-Prognostic-Biomarkers-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

 

Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.

 

While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options, these benefits are not seen in all patients and cancer types. Today, there is an urgent need for predictive biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic.

 

The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic therapy is in its early stages, however important advances have been made. This report identifies the latest findings on ten different cancers and includes an evaluation of candidate biomarkers as a basis for interpreting patient outcomes according to RECIST criteria, and evaluates existing bevacizumab-containing treatments and drug combinations.

 

Key content:

• A comprehensive review of clinical studies that have identified biomarkers that are either therapy-indicating in respect of bevacizumab (Avastin®) or indicative of patient prognosis

• Biomarkers identified or further evaluated in the last five years, up until January 2013. From a background of extensive research on bevacizumab (Avastin®) and VEGF-related biomarkers, the most important findings have been identified for their significance and value to patients and in designing clinical trials

• Covering more than ten cancers including colorectal, ovarian, renal, breast, pancreatic, prostate, lung and liver cancers

• Findings based on clinical trial findings including patient numbers, statistics and RECIST criteria

• Studies indicate drug type associations together with comparative therapies

• Descriptions and explanation of all biomarkers identified (proteins, genotypes, imaging etc)

• Biomarker associations are categorised according to three broad criteria, namely "positive-therapy-indicating" (response, improved response, improved outcome or prognosis), "non-therapy-indicating" (no differences in tumour response, outcome or prognosis) and "negative-therapy-indicating" (adverse events, poor outcome or prognosis).

 

 

 

Executive Summary

 

Chapter 1: Background (p.18)

 

1.1 VEGF Inhibition

1.2 Bevacizumab

1.3 Biomarkers

1.4 This Report

 

Chapter 2 Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p. 22)

 

Summary

2.1 Introduction

2.2 Glycoprotein

2.3 Protein

2.4 Protein

2.5 Cells

2.6 Genetic

2.7 Physical

2.8 Genetic

2.9 Protein

2.10 Proteins

2.11 Proteins and Genetic

2.12 Image

2.13 Proteins

2.14 Protein

 

Chapter 3 Breast Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.42)

 

Summary

3.1 Introduction

3.2 Protein

3.3 Protein

3.4 Protein

3.5 Protein

3.6 Protein

3.7 Genetic

3.8 Protein

 

Chapter 4 Renal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.50)

 

Summary

4.1 Introduction

4.2 Image

4.3 Protein

4.4 Physical

4.5 Protein

4.6 Body Characteristic

 

Chapter 5 Ovarian Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.55)

 

Summary

5.1 Introduction

5.2 Proteins

5.3 Proteins

5.4 Proteins

5.5 Proteins

 

Chapter 6 Lung Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.60)

 

Summary

6.1 Introduction

6.2 Physical Parameter

6.3 Protein

6.4 Genetic

6.5 Protein

 

Chapter 7 Liver Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.65)

 

Summary

7.1 Introduction

7.2 Protein

7.3 Image

 

Chapter 8 Other Cancers: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.71)

 

Summary

8.1 Introduction

8.2 Proteins

8.3 Proteins

8.4 Protein

8.5 Protein

8.6 Physical

8.7 Physical

8.8 Physical

 

Chapter 9: Discussion (p.80)

 

9.1 Overview

9.2 Colorectal Cancer

9.3 Breast Cancer:

9.4 Renal Cancer:

9.5 Ovarian Cancer

9.6 Lung Cancer

9.7 Liver Cancer

9.8 Other Cancers

9.9 Conclusions

 

 

 

Tables

 

Table 2.1 Candidates biomarkers identified in colorectal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 3.1 Candidates biomarkers identified in breast cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 4.1 Candidates biomarkers identified in renal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 5.1 Candidates biomarkers identified in ovarian cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 6.1 Candidates biomarkers identified in lung cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 7.1 Candidates biomarkers identified in liver cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 8.1 Candidates biomarkers identified in other cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.1 Protein candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.2 Genetic candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.3 Image-based candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.4 Other candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

 

 

 

Figures

 

Figure 9.1 Candidate biomarkers types identified in cancer patients receiving bevacizumab-containing therapies

Figure 9.2 Cancer types evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

Figure 9.3 Author countries (identified in this report) of cancers evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

 

 

 

To order this report:

Genomics Industry: VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Study confirms prognostic value of new IASLC/ATS/ERS adenocarcinoma sub-classification
2. Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson
3. EGFR mutation not prognostic factor in non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... 6, 2017 According to Acuity Market ... border authorities to continue to embrace biometric and ... 2143 Automated Border Control (ABC) eGates and 1436 ... more than 163 ports of entry across the ... achieving a combined CAGR of 37%. APC Kiosks ...
(Date:2/3/2017)... WASHINGTON , Feb. 3, 2017 A ... Identity Strategy Partners, LLP (IdSP) . Designed to ... in the complex identity market, founding partners Mark ... nearly 35 combined years just in identity expertise that ... tank and non-profit leadership. The Crego-Kephart combined expertise has ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... upscale Capitol Hill neighborhood, with its swanky shops, parks and cafés, ... treatment salon to set up shop. But there,s Hair ... bistro on E Madison Ave, and CEO Maria Botham ... clinic, we pride ourselves on being a destination for parents ... stigma associated with lice. Everyone can get lice – it ...
(Date:2/23/2017)... ... 2017 , ... Today, researchers can fast-track sample collection and ... other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the ... between insulin and other relevant biomarkers can be extensively studied through a non-invasive ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one members ... named Fellows of the Society this year, the Fellows Committee has announced. The ... of optics, photonics, and imaging as well as their service to the Society ...
(Date:2/22/2017)... 22, 2017 Scientists propose in Nature ... damage in Gaucher and maybe other lysosomal storage diseases ... costs than current therapies. An international research ... , which also included investigators from the University of ... data Feb. 22. The study was conducted in mouse ...
Breaking Biology Technology: